IE 11 is not supported. For an optimal experience visit our site on another browser.

VIVUS Inc. is Today's Focus Stock on

/ Source: GlobeNewswire

DALLAS, Sept. 16, 2010 (GLOBE NEWSWIRE) -- announces an investment report featuring VIVUS Inc. (Nasdaq:VVUS). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at:

VIVUS Inc. (VVUS) is a pharmaceutical company focused on the development and commercialization of therapeutic products. The Company's product pipeline includes three late-stage clinical products, each addressing specific components of the obesity, diabetes and sexual health markets. One of these investigational products, Qnexa, is in phase III clinical trials for obesity and in phase II clinical trials for diabetes. The Company's late-stage investigational product pipeline includes Qnexa for treating obesity, for which two of the phase III studies are in process and one phase III study has been completed; Qnexa for treating diabetes, for which a one-year phase II study has been completed; Avanafil, which is being developed for the treatment of erectile dysfunction, for which phase III studies are in process; and Luramist (Testosterone MDTS), which is being developed to treat hypoactive sexual desire disorder in women, for which a phase II study has been completed. 

Message Board Search for VVUS:

In the report, the analyst notes:

"Product revenues from the sale of MUSE in the second quarter of 2010 were $3.8 million as compared to $4.1 million in the second quarter of 2009 due to a small decrease in U.S. shipments. Total revenue for the second quarter of 2010 was $3.9 million as compared to $14.7 million for the second quarter of 2009.  

"Qnexa (Q-NEX-uh) is VVUS' investigational drug candidate being developed to address weight loss. Qnexa is a once-a-day, proprietary, oral, controlled-release formulation of low dose phentermine and topiramate, which is believed to address both appetite and satiety - the two main mechanisms that impact eating behavior - in one capsule."

To read the entire report visit:

See what investors are saying about VVUS at

Get breaking news on VVUS at is a small-cap research and investment commentary provider. strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: Disclosure is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. is a Web site wholly owned by BlueWave Advisors, LLC. Neither nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site,, for complete risks and disclosures.

CONTACT: Brian Johnson 1-888-307-2850